CClinicalTrials.gg
Not yet recruitingNCT07841223Updated Sep 25, 2026

Transoral Nasal Cannula Oxygen Therapy for Mouth-Breathing Patients in the Postanesthesia Care Unit

An interventional study of Transoral nasal cannula oxygen delivery in Postoperative Hypoxemia, sponsored by Nanjing First Hospital, Nanjing Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Nanjing First Hospital, Nanjing Medical University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Postoperative hypoxemia is a common complication in the postanesthesia care unit (PACU). Patients who breathe through the mouth after tracheal extubation may receive limited benefit from standard nasal cannula oxygen therapy, because the nasal cavity functions as an ineffective dead space during mouth breathing. Clinical observations suggest that placing the prongs of a nasal cannula inside the mouth (transoral oxygen delivery) rapidly improves oxygenation in these patients. However, no randomized controlled trial has formally verified this effect.

This single-center, randomized, controlled, crossover trial will enroll 64 adult patients identified as persistent mouth breathers after extubation in the PACU following elective thoracic or abdominal surgery under general anesthesia. Each participant will receive, in a randomized sequence, both standard nasal cannula oxygen delivery (4 L/min for 10 minutes) and transoral nasal cannula oxygen delivery (4 L/min for 10 minutes), separated by a 5-minute washout period, so that each participant serves as his or her own control.

The primary outcome is the incidence of hypoxemia (peripheral oxygen saturation [SpO2] \<90% sustained for at least 10 seconds, or oxygenation index [PaO2/FiO2 ratio] \<300 mmHg) during each oxygen delivery period. Secondary outcomes include the incidence of SpO2 \<92%, time to achieve SpO2 >=95%, oxygenation index measured by arterial blood gas analysis, need for escalation of oxygen therapy, vital signs, patient comfort and adverse effects, PACU length of stay, and respiratory complications within 24 hours after surgery. The results are expected to provide high-level evidence for optimizing oxygen therapy strategies for mouth-breathing patients in the PACU.

Read the detailed description

This is a single-center, randomized, controlled, crossover trial conducted in the Department of Anesthesiology, Pain and Perioperative Medicine, Nanjing First Hospital, Nanjing Medical University, China.

Screening and assessment of mouth breathing: Adult patients recovering from general anesthesia for elective thoracic or abdominal surgery are assessed 5 minutes after tracheal extubation using a standardized three-step procedure: (1) visual screening (lip separation >0.5 cm, visible anterior teeth, and lowered mandibular position, observed for 0-10 s); (2) airflow verification using cotton fiber wisps placed approximately 1 cm in front of both nostrils and the lips to identify the dominant ventilation pathway (10-25 s); and (3) mirror confirmation of exhaled vapor condensation together with observation of tongue position (25-40 s). Persistent mouth breathing is confirmed when all three steps are positive and no spontaneous mouth closure lasting more than 3 seconds occurs during the 40-second observation period.

Interventions: (a) Standard nasal cannula oxygen delivery: a standard dual-prong nasal cannula is placed in both nostrils with an oxygen flow of 4 L/min for 10 minutes. (b) Transoral nasal cannula oxygen delivery: the two prongs of the same nasal cannula are joined and placed in the oral vestibule at the inner aspect of the mouth corner (approximately at the buccal mucosa corresponding to the first molar), to a depth of no more than 3 cm, with an oxygen flow of 4 L/min for 10 minutes. A 5-minute washout period, during which nasal oxygen delivery is resumed, separates the two intervention periods.

Randomization and sequence: Eligible participants are randomly assigned in a 1:1 ratio to one of two sequences. Sequence A (nasal first): nasal oxygen delivery for 10 minutes, 5-minute washout, then transoral oxygen delivery for 10 minutes. Sequence B (transoral first): transoral oxygen delivery for 10 minutes, 5-minute washout, then nasal oxygen delivery for 10 minutes.

Measurements: SpO2 is monitored continuously throughout all periods. Arterial blood gas is sampled at minute 10 of each intervention period through the indwelling radial arterial catheter placed for routine intraoperative monitoring (approximately 1 mL per sample) to calculate the oxygenation index (PaO2/FiO2 ratio). Vital signs, comfort scores, and adverse effects are recorded at predefined time points.

Safety management: Continuous pulse oximetry is maintained throughout the study. Predefined safety exit criteria are applied (e.g., SpO2 \<85% sustained for more than 2 minutes, or SpO2 \<88% during any intervention); oxygen therapy is escalated immediately (face mask, reservoir mask, high-flow nasal cannula, or noninvasive ventilation) whenever clinically indicated, and an anesthesiologist is present in the PACU at all times. The same cannula is disinfected with cotton swabs when switched between the nasal and oral routes to prevent cross-infection.

02

Conditions studied

  • Postoperative Hypoxemia

Keywords

  • Nasal cannula
  • Transoral oxygen delivery
  • Postanesthesia care unit (PACU)
  • Oxygen therapy
  • Crossover trial
  • Pulse oximetry (SpO2)
  • Oxygenation index
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged older than 18 years;
  2. American Society of Anesthesiologists (ASA) physical status classification I-III;
  3. Undergoing elective thoracic or abdominal surgery under general anesthesia with postoperative transfer to the postanesthesia care unit (PACU);
  4. Anticipated PACU stay of at least 30 minutes to allow an adequate observation window for data collection;
  5. Recovery of spontaneous breathing after tracheal extubation, and confirmed as persistent mouth breathing by the standardized three-step assessment procedure (visual screening, cotton-fiber airflow verification, and mirror confirmation);
  6. Written informed consent signed by the patient or a family member.

Exclusion criteria

Exclusion Criteria:

  1. Preoperative diagnosis of severe obstructive sleep apnea-hypopnea syndrome (apnea-hypopnea index [AHI] >30) or requirement for continuous positive airway pressure therapy;
  2. Severe hypoxemia requiring immediate escalation of oxygen therapy (SpO2 \<90% or PaO2 \<60 mmHg);
  3. Requirement for reintubation or placement of an oropharyngeal or nasopharyngeal airway after surgery;
  4. Hemodynamic instability requiring vasoactive agents to maintain mean arterial pressure (MAP \<65 mmHg).
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    Sequence ON: Transoral oxygen first, then nasal oxygen

    Participants receive transoral nasal cannula oxygen delivery (4 L/min for 10 minutes), followed by a 5-minute washout period (nasal oxygen delivery resumed), and then standard nasal cannula oxygen delivery (4 L/min for 10 minutes).

    Other: Transoral nasal cannula oxygen delivery

  • Active comparator
    Sequence NO: Nasal oxygen first, then transoral oxygen

    Participants receive standard nasal cannula oxygen delivery (4 L/min for 10 minutes), followed by a 5-minute washout period (nasal oxygen delivery resumed), and then transoral nasal cannula oxygen delivery (4 L/min for 10 minutes).

    Other: Transoral nasal cannula oxygen delivery

Interventions

  • OtherTransoral nasal cannula oxygen delivery

    The two prongs of a standard dual-prong nasal cannula are joined and placed in the oral vestibule at the inner aspect of the mouth corner (approximately at the buccal mucosa corresponding to the first molar), to a depth of no more than 3 cm to avoid stimulating the gag reflex. Oxygen flow is set at 4 L/min with standard humidification for 10 minutes.

05

What researchers measure

Primary outcomes

  1. Incidence of hypoxemia during the oxygen delivery periods

    Hypoxemia is defined as peripheral oxygen saturation (SpO2) \<90% sustained for at least 10 seconds, or an oxygenation index (PaO2/FiO2 ratio) \<300 mmHg measured by arterial blood gas analysis at minute 10 of the intervention period. The outcome is reported as the proportion of participants experiencing hypoxemia during the nasal oxygen delivery period compared with the transoral oxygen delivery period.

    Time frame: During each 10-minute oxygen delivery period in the PACU (each participant undergoes two consecutive intervention periods)

Secondary outcomes

  1. Incidence of SpO2 <92%

    Proportion of participants with peripheral oxygen saturation (SpO2) \<92% at any time during each oxygen delivery period.

    Time frame: During each 10-minute oxygen delivery period in the PACU

  2. Oxygenation index (PaO2/FiO2 ratio)

    Calculated from arterial blood gas sampled through the indwelling radial arterial catheter at minute 10 of each intervention period; compared between the nasal and transoral oxygen delivery periods.

    Time frame: At minute 10 of each 10-minute oxygen delivery period

  3. Time to achieve SpO2 >=95%

    Time elapsed from the beginning of each intervention until peripheral oxygen saturation reaches \>=95%.

    Time frame: From the start of each oxygen delivery period, up to 10 minutes

  4. Proportion of participants requiring escalation of oxygen therapy

    Proportion of participants requiring escalation to a simple face mask (\>=6 L/min), reservoir mask, high-flow nasal cannula (HFNC), or noninvasive ventilation (NIV) because of SpO2 \<90% or respiratory distress.

    Time frame: Throughout the PACU stay (up to 24 hours after surgery)

  5. Respiratory rate

    Respiratory rate (breaths/min) recorded at each predefined time point.

    Time frame: Preoperatively; at the start of surgery; at the end of surgery; after extubation; 1 minute before and 1 minute after each change of oxygen delivery route; at PACU discharge

  6. Heart rate

    Heart rate (beats/min) recorded at each predefined time point.

    Time frame: Preoperatively; at the start of surgery; at the end of surgery; after extubation; 1 minute before and 1 minute after each change of oxygen delivery route; at PACU discharge

  7. Mean arterial pressure (MAP)

    Mean arterial pressure (mmHg) recorded at each predefined time point.

    Time frame: Preoperatively; at the start of surgery; at the end of surgery; after extubation; 1 minute before and 1 minute after each change of oxygen delivery route; at PACU discharge

  8. Airway plateau pressure

    Airway plateau pressure (cmH2O) recorded from the anesthesia ventilator.

    Time frame: At the start and at the end of surgery

  9. Positive end-expiratory pressure (PEEP)

    Positive end-expiratory pressure (cmH2O) recorded from the anesthesia ventilator.

    Time frame: At the start and at the end of surgery

  10. Oral dryness score

    Oral dryness assessed with a visual analog scale (VAS) ranging from 0 to 10, where 0 indicates no dryness and 10 indicates the worst imaginable dryness. Higher scores indicate worse (more severe) dryness.

    Time frame: Immediately after completion of each 10-minute oxygen delivery period

  11. Overall comfort score

    Overall comfort assessed with a visual analog scale (VAS) ranging from 0 to 10, where 0 indicates maximal discomfort and 10 indicates maximal comfort. Higher scores indicate better comfort.

    Time frame: Immediately after completion of each 10-minute oxygen delivery period

  12. Pharyngeal irritation / nausea score

    Patient-reported pharyngeal irritation and nausea, each graded on a 4-point scale: 0 = none, 1 = mild (symptoms present but tolerable), 2 = moderate (causing discomfort but not requiring intervention), 3 = severe (requiring intervention). Higher scores indicate worse symptoms.

    Time frame: Immediately after completion of each 10-minute oxygen delivery period

  13. Length of PACU stay

    Total duration of stay in the postanesthesia care unit, in minutes.

    Time frame: From PACU admission to PACU discharge (up to 24 hours after surgery)

  14. Respiratory complications within 24 hours after surgery

    Composite of reintubation, pneumonia, atelectasis, and requirement for prolonged oxygen therapy, reported as the number and proportion of participants with each event.

    Time frame: Within 24 hours after surgery

06

Study locations

1 site
  • Nanjing First Hospital, Nanjing Medical University
    Nanjing, Jaingsu 210006, China
07

References and documents

Individual participant data

Plan to share: Yes — All data relevant to the study are included in the article. Data supporting the findings are available from the corresponding author upon reasonable request.

Supporting information: Study protocol, Sap, Icf, Csr

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07841223
Lead sponsor
Nanjing First Hospital, Nanjing Medical University
Responsible party
Shuai Wang (Deputy Chief Nurse, Nanjing First Hospital, Nanjing Medical University) — Principal investigator
First posted
Sep 25, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Shuai Wang
Contact
wangshuaisj@126.com
+8618852095101
YING ZHANG
Contact
025-52271064
Shuai Wang
principal investigator · Nanjing First Hospital, Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion